J
J. Donald Easton
Researcher at University of California, San Francisco
Publications - 113
Citations - 22677
J. Donald Easton is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Stroke & Aspirin. The author has an hindex of 42, co-authored 104 publications receiving 20175 citations. Previous affiliations of J. Donald Easton include Brown University & Stanford University.
Papers
More filters
Journal ArticleDOI
Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association.
José Biller,William Feinberg,John E. Castaldo,Anthony D. Whittemore,Robert E. Harbaugh,Robert J. Dempsey,Louis R. Caplan,Timothy F. Kresowik,David B. Matchar,James F. Toole,J. Donald Easton,Harold P. Adams,Lawrence M. Brass,Robert W. Hobson,Thomas G. Brott,Linda Sternau +15 more
TL;DR: A wealth of data are available regarding the general relationship between risk factor control and stroke risk and these data provide some guidance for the care of endarterectomy patients, including careful control of hypertension.
Journal ArticleDOI
Immediate anticoagulation of embolic stroke: brain hemorrhage and management options
Robert G. Hart,Kathleen I. Lock-Wood,Antoine M. Hakim,Richard L. Koller,John G. Davenport,Bruce M. Coull,Robin L. Brey,Anthony J. Furlan,Bernard J. O'neill,L. Creed Pettigrew,Avindra Nath,Frank M. Yatsu,David G. Sherman,J. Donald Easton,Vincent T. Miller +14 more
TL;DR: The clinical implications of hemorrhagic transformation of embolic brain infarction were explored by studying 30 patients with cardiogenic brain embolism and either hemorrhagic infarct (HI) or intracerebral hematoma on CT, finding a delay of several days before anticoagulation and special efforts to avoid excessive anticoageulation and hypertension may be prudent.
Journal ArticleDOI
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
J. Donald Easton,Renato D. Lopes,M. Cecilia Bahit,Daniel Wojdyla,Christopher B. Granger,Lars Wallentin,Marco Alings,Shinya Goto,Basil S. Lewis,Mårten Rosenqvist,Michael G. Hanna,Puneet Mohan,John H. Alexander,Hans-Christoph Diener +13 more
TL;DR: The effects of apixaban versus warfarin were consistent in patients with AF with and without previous stroke or TIA, and the absolute benefits of apxaban might be greater in this population.
Journal ArticleDOI
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial
Eric J. Topol,Marie-Germaine Bousser,Keith A.A. Fox,Mark A. Creager,Jean-Pierre Després,J. Donald Easton,Christian W. Hamm,Gilles Montalescot,P. Gabriel Steg,Thomas A. Pearson,Eric A. Cohen,Christophe Gaudin,Bernard Job,Judith H Murphy,Deepak L. Bhatt +14 more
TL;DR: A drug that was being marketed for weight loss, but being tested for improving cardiovascular outcomes, induced a level of serious neuropsychiatric effects that was deemed unacceptable by regulatory authorities, and both the drug and the trial were abruptly terminated.
Journal ArticleDOI
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
John W. Eikelboom,Graeme J. Hankey,J. Thom,Deepak L. Bhatt,P. Gabriel Steg,Gilles Montalescot,S. Claiborne Johnston,Steven R. Steinhubl,Koon Hou Mak,J. Donald Easton,Christian W. Hamm,Tingfei Hu,Keith A.A. Fox,Eric J. Topol +13 more
TL;DR: In aspirin-treated patients, urinary concentrations of 11-dehydro thromboxane B2 are an externally valid and potentially modifiable determinant of stroke, myocardial infarction, or cardiovascular death in patients at risk for atherothrombotic events.